Cargando…
The Value of Phenotypic Precision Medicine in Prostate Cancer
Prostate cancer is the most common cancer among men and the second leading cause of cancer-related death. For patients who develop metastatic disease, tissue-based and circulating-tumor–based molecular and genomic biomarkers have emerged as a means of improving outcomes through the application of pr...
Autores principales: | Hawkey, Nathan M, Broderick, Amanda, George, Daniel J, Sartor, Oliver, Armstrong, Andrew J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907055/ https://www.ncbi.nlm.nih.gov/pubmed/36200788 http://dx.doi.org/10.1093/oncolo/oyac198 |
Ejemplares similares
-
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
por: Ramnaraign, Brian, et al.
Publicado: (2023) -
Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies
por: Thiery‐Vuillemin, Antoine, et al.
Publicado: (2021) -
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Freeman, Meredith N, et al.
Publicado: (2022) -
Results of a Prospective Dose Escalation Study of Linear Accelerator–Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer
por: Eade, Thomas, et al.
Publicado: (2019) -
Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience
por: Lee, Howard J., et al.
Publicado: (2018)